Wegovy Titelbild

Wegovy

Wegovy

Von: Liquid Studios
Jetzt kostenlos hören, ohne Abo

Saisonale Sparangebote | 0,99 € pro Monat für die ersten 3 Monate

Danach 6,99 €/Monat. Bedingungen gelten. Monatlich kündbar.
This series on Wegovy provides an in-depth look into the popular weight loss medication. The first episode introduces Wegovy, explaining its mechanism, clinical trials, and patient eligibility. The second episode delves into the benefits and potential risks, including effectiveness, side effects, and comparisons with other treatments. The final episode covers practical considerations such as usage, lifestyle integration, cost, and future developments. This series offers a comprehensive understanding for anyone considering Wegovy as a weight management solution. This content was created in partnership and with the help of Artificial Intelligence AI.Copyright 2026 Liquid Studios Hygiene & gesundes Leben
Folgen
  • Wegovy Expands Globally With Oral Tablets, Public Health Coverage Debates, and Manufacturing Investments

    Wegovy Expands Globally With Oral Tablets, Public Health Coverage Debates, and Manufacturing Investments
    Oct 20 2026
    # Wegovy's Next Chapter: Pills, Pricing Wars & Billion-Euro Decisions **Episode Description:** Wegovy is no longer just a weekly injection — it's becoming a global pharmaceutical battleground. In this episode, we unpack the biggest semaglutide headlines reshaping obesity treatment, healthcare policy, and pharma competition worldwide. We dive into Ireland's health technology assessment recommending Wegovy for public reimbursement — and the staggering €4.4 billion five-year cost projection that comes with it. We head to South Korea, where Novo Nordisk is seeking national insurance coverage amid surging prescriptions and new local competitors entering the weight-loss drug market at lower prices. Then we explore the rise of **oral semaglutide**, newly approved in the EU, and how Eli Lilly's rival pill Foundayo could trigger a head-to-head battle for the future of obesity pills. We also look inside Novo Nordisk's highly automated Danish manufacturing facility, where a tenfold investment increase is powering global supply. Plus: new clinical data from the Step Up study suggests Wegovy may reduce liver fat in nearly 90% of patients — hinting at benefits that go far beyond weight loss. From Bahrain's approval of the oral tablet to looming Novo Nordisk earnings reports, this episode connects the dots on what's next for Wegovy, Mounjaro, and the rapidly evolving GLP-1 drug market. **Topics covered:** - Ireland's HSE Wegovy reimbursement decision & cost analysis - South Korea's insurance review and rising GLP-1 competition - EU approval of oral Wegovy vs. Eli Lilly's Foundayo - Novo Nordisk's manufacturing expansion and AI-driven production - New Step Up study findings on liver fat reduction - Bahrain's oral semaglutide approval - What's next for pricing, Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai
    Mehr anzeigen Weniger anzeigen
    8 Min.
  • Wegovy Access and Cost Debates Intensify Globally as Safety Questions Emerge Alongside Clinical Benefits

    Wegovy Access and Cost Debates Intensify Globally as Safety Questions Emerge Alongside Clinical Benefits
    Oct 17 2026
    # Wegovy's Global Reckoning: Cost, Access, Safety & the Future of Obesity Treatment **Episode Description:** Wegovy is making headlines again — but this time the story isn't just about weight loss. In this episode, we unpack the global tug-of-war over access, affordability, and safety surrounding Novo Nordisk's blockbuster semaglutide drug, and what it reveals about the future of obesity treatment worldwide. We break down Ireland's pivotal moment, where the National Centre for Pharmacoeconomics has greenlit Wegovy as cost-effective for public patients — but with a staggering potential price tag of €4.4 billion over five years. We head to Scotland, where NHS access remains painfully limited despite an estimated 300,000 people turning to private prescriptions, exposing a widening gap between those who can pay and those who can't. Then we look to South Korea, where Novo Nordisk is pushing for national insurance reimbursement amid fierce price competition with Eli Lilly's Mounjaro. Beyond the cost debate, we explore the expanding science behind semaglutide — including promising new data on liver fat reduction and its potential role in treating MASH (metabolic dysfunction-associated steatohepatitis). But it's not all good news: we also examine a Rutgers-led study linking GLP-1 medications to a rare risk of vision loss called ischemic optic neuropathy, and what patients need to know. Finally, we look ahead to the next frontier — oral semaglutide, tirzepatide competition, and a pipeline of over 200 companies racing to build the next generation of obesity drugs. Whether you're a patient, healthcare provider, or just following the GLP-1 revolution, this episode delivers a clear-eyed look at where Wegovy stands today — and the hard questions healthcare systems, doctors, and patients will face next. **Topics covered:** Wegovy cost and access, sema Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai
    Mehr anzeigen Weniger anzeigen
    8 Min.
  • Wegovy Faces Global Competition as South Korea Seeks Insurance Coverage and Novo Nordisk Develops Oral Alternative

    Wegovy Faces Global Competition as South Korea Seeks Insurance Coverage and Novo Nordisk Develops Oral Alternative
    Oct 13 2026
    # Wegovy's Global Battle: Insurance Fights, Oral Pills & Rising Competition from Eli Lilly **Episode Description:** The Wegovy story has evolved far beyond a weekly injection and weight loss numbers — it's now a global battle over healthcare access, pricing, and the future of obesity treatment. In this episode, we break down the latest developments shaking up the obesity drug market worldwide. **What we cover:** 🇰🇷 **South Korea's Insurance Showdown** – Novo Nordisk has formally applied for national health insurance reimbursement for Wegovy through South Korea's HIRA agency, seeking coverage for adolescent obesity, severe obesity, and cardiovascular risk reduction. We explain what this means for patient affordability and the regulatory hurdles ahead. 💊 **Domestic Competition Heats Up** – Hanmi Pharmaceutical's new obesity drug "Efpe" is set to launch in South Korea, offering a homegrown alternative to Wegovy — even if clinical results show slightly lower weight loss outcomes. 📈 **The Oral Wegovy Opportunity** – Citi analysts project the Wegovy tablet could generate $13 billion in annual sales. We discuss why a pill form could be a game-changer for needle-averse patients and what it means for Novo Nordisk's market position. ⚔️ **Eli Lilly's Growing Threat** – Mounjaro and Zepbound are gaining ground, with some reports showing Lilly's drugs overtaking Ozempic and Wegovy in key prescription metrics. Plus, we unpack Novo Nordisk's disappointing CagriSema trial results. 🩺 **New Liver Health Findings** – Fresh data presented at the European Association for the Study of Diabetes meeting reveals promising reductions in liver fat among semaglut Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai
    Mehr anzeigen Weniger anzeigen
    8 Min.
adbl_web_anon_alc_button_suppression_t1
Noch keine Rezensionen vorhanden